Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
$3.20
+4.8%
$2.94
$1.05
$3.98
$302.49M1.89601,651 shs461,067 shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$4.67
+7.9%
$3.99
$2.13
$10.00
$295.17M0.58841,882 shs707,908 shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$4.30
-3.4%
$4.35
$3.62
$9.18
$32.51M0.654,706 shs114,320 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.42
+2.5%
$0.67
$0.30
$4.28
$19.72M-0.061.48 million shs2.45 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
+4.58%+4.24%+19.22%+135.79%-17.23%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
+7.85%+9.88%+25.20%+27.60%+109.42%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-3.37%-4.44%+0.94%-9.47%-31.97%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+2.51%+9.69%-39.37%-53.22%-59.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
1.3249 of 5 stars
3.51.00.00.00.00.80.6
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
1.9477 of 5 stars
3.51.00.00.00.03.30.6
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
3.856 of 5 stars
3.22.00.04.60.03.30.6
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.7231 of 5 stars
3.62.00.00.01.13.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
3.00
Buy$7.75142.57% Upside
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3.00
Buy$15.00221.20% Upside
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
2.33
Hold$39.50818.60% Upside
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
3.29
Buy$9.002,037.77% Upside

Current Analyst Ratings Breakdown

Latest RVPH, KZR, ADCT, and CRVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
6/27/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
6/20/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.00
6/13/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $10.00
6/3/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
5/20/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$12.00 ➝ $11.00
5/20/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $3.00
5/15/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.00
5/9/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.00
4/24/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
$70.84M4.47N/AN/A($2.10) per share-1.52
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/A$0.51 per shareN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7M4.49N/AN/A$16.02 per share0.27
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$0.02 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
-$157.85M-$1.45N/AN/AN/A-197.64%N/A-45.57%8/5/2025 (Estimated)
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$62.29M-$0.98N/AN/AN/AN/A-24.04%-13.90%8/5/2025 (Estimated)
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$29.92M-$0.79N/AN/AN/AN/AN/A-302.31%8/13/2025 (Estimated)

Latest RVPH, KZR, ADCT, and CRVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.15N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.25N/AN/AN/AN/AN/A
8/5/2025Q2 2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
-$0.36N/AN/AN/A$17.82 millionN/A
8/5/2025Q2 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.21-$0.13+$0.08-$0.13N/AN/A
5/14/2025Q1 2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 million
5/13/2025Q1 2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.56-$2.27+$0.29-$2.27N/AN/A
5/8/2025Q1 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13-$0.13N/A-$0.13N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
N/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
N/A
4.46
4.16
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
4.90
4.90
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.04
7.09
7.09
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
0.54
0.54

Institutional Ownership

CompanyInstitutional Ownership
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
41.10%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
67.90%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%

Insider Ownership

CompanyInsider Ownership
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
5.40%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
28.50%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
10.40%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
27.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
31099.18 million93.82 millionOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3068.17 million48.74 millionOptionable
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
607.31 million6.55 millionNot Optionable
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
548.00 million34.96 millionOptionable

Recent News About These Companies

Reviva Dives on Stock Offering
RVPH: M&A Deals Highlight Brilaroxazine Value
Unusually active option classes on open February 12th

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADC Therapeutics stock logo

ADC Therapeutics NYSE:ADCT

$3.20 +0.15 (+4.75%)
Closing price 07/23/2025 03:59 PM Eastern
Extended Trading
$3.17 -0.02 (-0.78%)
As of 07/23/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$4.67 +0.34 (+7.85%)
Closing price 07/23/2025 04:00 PM Eastern
Extended Trading
$4.60 -0.07 (-1.50%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Kezar Life Sciences stock logo

Kezar Life Sciences NASDAQ:KZR

$4.30 -0.15 (-3.37%)
Closing price 07/23/2025 04:00 PM Eastern
Extended Trading
$4.33 +0.03 (+0.70%)
As of 07/23/2025 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.42 +0.01 (+2.51%)
Closing price 07/23/2025 04:00 PM Eastern
Extended Trading
$0.42 -0.01 (-1.43%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.